- Home
- CMPR vs ZLAB Comparison
CMPR vs ZLAB Comparison
Compare CMPR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMPR | ZLAB |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | Ireland | China |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2005 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CMPR | ZLAB |
|---|---|---|
| Price | $72.22 | $17.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $86.50 | $49.60 |
| AVG Volume (30 Days) | 89.1K | ★ 639.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ 2.26 | N/A |
| Revenue | ★ $3,403,079,000.00 | $460,156,000.00 |
| Revenue This Year | $10.43 | $14.46 |
| Revenue Next Year | $5.46 | $29.47 |
| P/E Ratio | $30.68 | ★ N/A |
| Revenue Growth | 3.38 | ★ 15.33 |
| 52 Week Low | $35.28 | $15.96 |
| 52 Week High | $82.43 | $44.34 |
Technical Indicators
Market Signals| Indicator | CMPR | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 39.87 |
| Support Level | $71.12 | $17.03 |
| Resistance Level | $75.75 | $19.71 |
| Average True Range (ATR) | 2.59 | 0.66 |
| MACD | 0.14 | -0.15 |
| Stochastic Oscillator | 87.60 | 12.22 |
Price Performance
Historical ComparisonAbout CMPR Cimpress plc (Ireland)
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.